Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded, Randomized, Placebo-controlled Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV Negative Women

NCT07810062 is registered in ClinicalTrials.gov with Centre for Infectious Disease Research in Zambia as lead sponsor.

NCT NCT07810062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07810062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded, Randomized, Placebo-controlled Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV Negative Women
Lead sponsor
Centre for Infectious Disease Research in Zambia
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2023
Completion date
June 30, 2025
Enrollment
990 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

to assess extended safety and tolerability of subcutaneous cap256v2ls and vrc07-523ls monoclonal antibodies in hiv-negative women